bluebird bio (NASDAQ:BLUE) had its price target decreased by Cantor Fitzgerald from $122.00 to $113.00 in a research report released on Thursday morning. Cantor Fitzgerald currently has an underweight rating on the biotechnology company’s stock.
Several other research analysts have also recently commented on the stock. Maxim Group reiterated a buy rating and issued a $170.00 target price on shares of bluebird bio in a report on Thursday, November 2nd. BTIG Research upgraded shares of bluebird bio from a neutral rating to a buy rating and set a $177.00 target price for the company in a report on Thursday, November 2nd. BMO Capital Markets raised their target price on shares of bluebird bio from $134.00 to $162.00 and gave the stock a buy rating in a report on Monday, October 30th. Jefferies Group upgraded shares of bluebird bio from a hold rating to a buy rating and raised their target price for the stock from $130.00 to $211.00 in a report on Monday, December 11th. Finally, Canaccord Genuity assumed coverage on shares of bluebird bio in a report on Tuesday, December 5th. They issued a buy rating and a $202.00 target price for the company. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. bluebird bio currently has a consensus rating of Hold and an average target price of $173.05.
bluebird bio (NASDAQ BLUE) traded down $6.20 during trading hours on Thursday, hitting $201.20. 1,085,400 shares of the stock traded hands, compared to its average volume of 869,019. bluebird bio has a one year low of $74.45 and a one year high of $222.03. The company has a market cap of $9,860.00, a price-to-earnings ratio of -26.28 and a beta of 2.07.
In other news, insider Philip D. Gregory sold 2,250 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $172.54, for a total value of $388,215.00. Following the completion of the sale, the insider now directly owns 28,734 shares of the company’s stock, valued at $4,957,764.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Susanna Gatti High sold 1,282 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the completion of the sale, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at $2,361,553.70. The disclosure for this sale can be found here. Insiders sold 200,280 shares of company stock valued at $37,818,846 over the last three months. 3.90% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of BLUE. Meeder Asset Management Inc. lifted its position in shares of bluebird bio by 2,110.3% in the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 612 shares in the last quarter. QS Investors LLC raised its position in bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 500 shares in the last quarter. NuWave Investment Management LLC bought a new position in bluebird bio during the fourth quarter valued at approximately $135,000. Ladenburg Thalmann Financial Services Inc. raised its position in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 813 shares in the last quarter. Finally, Biondo Investment Advisors LLC bought a new position in bluebird bio during the third quarter valued at approximately $203,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.